Aduro shows survival benefit with pancreatic cancer vaccine duo
This article was originally published in Scrip
Executive Summary
Private US biotech company Aduro BioTech has reported a survival benefit in metastatic pancreatic cancer with its combination immunotherapy-based treatment, in a Phase II trial that was stopped early on the strength of the data after a pre-planned interim analysis.
You may also be interested in...
Immuno-Oncology's Next Wave: Key Targets And Emerging Players
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.
New Phase II Data Bolster vTv Therapeutics’ Glucokinase Activator Aspirations
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed Goes Full Steam Ahead With Bronchiectasis Candidate
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.
Need a specific report? 1000+ reports available
Buy Reports